This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Healthcare IPOs: Horizon, WhiteGlove

NEW YORK ( TheStreet -- This week's IPO calendar features two very different health care companies.

Horizon Pharmaceuticals (HZNP - Get Report) is looking to raise a little more than $60 million through the sales of 5.5 million shares at an estimate range of $10-$12 each. The Northbrook, Ill.-based company plans to use the funds it generates to market its latest drugs in the United States.

Specifically, it's earmarked $37 million to fund commercial activities for Duexis, a pain treatment, and Lodotra, an arthritis pill.

Duexis is tablet that combines ibuprofen and famotidine in a single pill. It looks to be the only drug with this combination on the market. Horizon has already submitted a marketing application for Duexis in the United Kingdom and expects a decision in the first half of 2012.

Lodotra is a low-dose prednisone that is currently marketed in Europe by Mundipharma. The product will compete with Pfizer's (PFE - Get Report) Celebrex.

Competition is a concern. Horizon is going up against some of the biggest names in the pharmaceutical business, companies with successful products and deep pockets.

Francis Gaskins, the president of IPO Desktop, suggests that investors wait to see what regulatory reception the drugs receive before buying. Granted, the stock may gain in value by that time, but he believes it is prudent to wait.

"The company is hemorrhaging cash right now," Gaskins says.

At least Horizon has a clear story though.

WhiteGlove House Call Health (WGH) is a company that is less easily understood. It has a new, but unproven business model that seeks to lower health care costs by providing membership-based health care delivery.

The Austin, Texas-based company competes with regular doctors, retail clinics and traditional emergency room hospitals. WhiteGlove is not a health insurance plan. It charges its members a fixed cost, but then provides them with telephone consultations, prescriptions and testing services. The service covers minor ailments like colds, flus, skin rashes, lab work and physicals. The company also provides some chronic care for blood pressure, cholesterol and diabetes.

WhiteGlove plans to raise $28 million through the sale of 2.5 million shares at an estimate range of $9-$13 each. The company wants to use the money to pay down debt and expand into new markets.

Unfortunately, WhiteGlove isn't profitable and revenues have been uneven. It's difficult to compare WhiteGlove with other companies because of its unique business model. It was established in 2006 with a network of nurse practitioners. As of June, WhiteGlove had 484,000 members in Texas, Arizona and Massachusetts. It's definitely a speculative play for investors.

-- Written by Debra Borchardt in New York.

>To contact the writer of this article, click here: Debra Borchardt.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HZNP $14.71 -3.40%
PFE $33.44 -0.77%
AAPL $94.02 -1.20%
FB $117.54 0.09%
GOOG $696.13 0.54%


Chart of I:DJI
DOW 17,654.38 -96.53 -0.54%
S&P 500 2,049.94 -13.43 -0.65%
NASDAQ 4,724.6070 -38.6170 -0.81%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs